Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.
The objective of this study was to assess the risk of cancer in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs). We analysed the 2000-2023 data for RA patients from the BIOBADASER III registry, a multicentre national registry of patients treated…